vs
ASSOCIATED BANC-CORP（ASB）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
ASSOCIATED BANC-CORP的季度营收约是Orthofix Medical Inc.的1.7倍（$383.0M vs $219.9M），ASSOCIATED BANC-CORP净利率更高（31.2% vs -1.0%，领先32.2%），过去两年ASSOCIATED BANC-CORP的营收复合增速更高（9.1% vs 8.0%）
联合银行集团（Associated Banc-Corp）是美国区域性银行控股公司，总部位于威斯康星州格林贝，深耕美国中西部地区，主营零售银行、商业银行、商业地产贷款、私人银行及特色金融服务，在威斯康星州、伊利诺伊州、明尼苏达州设有220多个营业网点，覆盖100多个社区，还在印第安纳、密歇根等多州设有贷款办事处。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
ASB vs OFIX — 直观对比
营收规模更大
ASB
是对方的1.7倍
$219.9M
净利率更高
ASB
高出32.2%
-1.0%
两年增速更快
ASB
近两年复合增速
8.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $383.0M | $219.9M |
| 净利润 | $119.6M | $-2.2M |
| 毛利率 | — | 71.1% |
| 营业利润率 | — | 0.2% |
| 净利率 | 31.2% | -1.0% |
| 营收同比 | — | 2.0% |
| 净利润同比 | 566.6% | 92.4% |
| 每股收益（稀释后） | $0.70 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASBOFIX
| Q1 26 | $383.0M | — | ||
| Q4 25 | $310.0M | $219.9M | ||
| Q3 25 | $305.2M | $205.6M | ||
| Q2 25 | $300.0M | $203.1M | ||
| Q1 25 | $285.9M | $193.6M | ||
| Q4 24 | $270.3M | $215.7M | ||
| Q3 24 | $329.7M | $196.6M | ||
| Q2 24 | $321.8M | $198.6M |
净利润ASBOFIX
| Q1 26 | $119.6M | — | ||
| Q4 25 | $137.1M | $-2.2M | ||
| Q3 25 | $124.7M | $-22.8M | ||
| Q2 25 | $111.2M | $-14.1M | ||
| Q1 25 | $101.7M | $-53.1M | ||
| Q4 24 | $-161.6M | $-29.1M | ||
| Q3 24 | $88.0M | $-27.4M | ||
| Q2 24 | $115.6M | $-33.4M |
毛利率ASBOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | 71.1% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 68.7% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | — | 68.7% | ||
| Q2 24 | — | 67.8% |
营业利润率ASBOFIX
| Q1 26 | — | — | ||
| Q4 25 | 52.6% | 0.2% | ||
| Q3 25 | 50.5% | -8.3% | ||
| Q2 25 | 46.5% | -7.9% | ||
| Q1 25 | 42.3% | -25.2% | ||
| Q4 24 | -65.8% | -5.3% | ||
| Q3 24 | 32.8% | -9.6% | ||
| Q2 24 | 32.0% | -12.5% |
净利率ASBOFIX
| Q1 26 | 31.2% | — | ||
| Q4 25 | 44.2% | -1.0% | ||
| Q3 25 | 40.9% | -11.1% | ||
| Q2 25 | 37.1% | -6.9% | ||
| Q1 25 | 35.6% | -27.4% | ||
| Q4 24 | -59.8% | -13.5% | ||
| Q3 24 | 26.7% | -13.9% | ||
| Q2 24 | 35.9% | -16.8% |
每股收益（稀释后）ASBOFIX
| Q1 26 | $0.70 | — | ||
| Q4 25 | $0.80 | $-0.05 | ||
| Q3 25 | $0.73 | $-0.57 | ||
| Q2 25 | $0.65 | $-0.36 | ||
| Q1 25 | $0.59 | $-1.35 | ||
| Q4 24 | $-1.10 | $-0.76 | ||
| Q3 24 | $0.56 | $-0.71 | ||
| Q2 24 | $0.74 | $-0.88 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $5.0B | $450.0M |
| 总资产 | $45.6B | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ASBOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | $82.0M | ||
| Q3 25 | — | $62.9M | ||
| Q2 25 | — | $65.6M | ||
| Q1 25 | — | $58.0M | ||
| Q4 24 | — | $83.2M | ||
| Q3 24 | — | $30.1M | ||
| Q2 24 | — | $26.4M |
总债务ASBOFIX
| Q1 26 | — | — | ||
| Q4 25 | $1.0B | — | ||
| Q3 25 | $594.1M | $157.2M | ||
| Q2 25 | $593.5M | $157.0M | ||
| Q1 25 | $591.4M | $156.9M | ||
| Q4 24 | $1.4B | $157.0M | ||
| Q3 24 | $844.3M | $118.5M | ||
| Q2 24 | $536.1M | $118.0M |
股东权益ASBOFIX
| Q1 26 | $5.0B | — | ||
| Q4 25 | $5.0B | $450.0M | ||
| Q3 25 | $4.9B | $442.5M | ||
| Q2 25 | $4.8B | $458.3M | ||
| Q1 25 | $4.7B | $458.3M | ||
| Q4 24 | $4.6B | $503.1M | ||
| Q3 24 | $4.4B | $525.9M | ||
| Q2 24 | $4.2B | $546.0M |
总资产ASBOFIX
| Q1 26 | $45.6B | — | ||
| Q4 25 | $45.2B | $850.6M | ||
| Q3 25 | $44.5B | $832.6M | ||
| Q2 25 | $44.0B | $837.2M | ||
| Q1 25 | $43.3B | $823.1M | ||
| Q4 24 | $43.0B | $893.3M | ||
| Q3 24 | $42.2B | $867.9M | ||
| Q2 24 | $41.6B | $882.0M |
负债/权益比ASBOFIX
| Q1 26 | — | — | ||
| Q4 25 | 0.20× | — | ||
| Q3 25 | 0.12× | 0.36× | ||
| Q2 25 | 0.12× | 0.34× | ||
| Q1 25 | 0.13× | 0.34× | ||
| Q4 24 | 0.31× | 0.31× | ||
| Q3 24 | 0.19× | 0.23× | ||
| Q2 24 | 0.13× | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $27.7M |
| 自由现金流经营现金流 - 资本支出 | — | $16.8M |
| 自由现金流率自由现金流/营收 | — | 7.6% |
| 资本支出强度资本支出/营收 | — | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-1.3M |
8季度趋势，按日历期对齐
经营现金流ASBOFIX
| Q1 26 | — | — | ||
| Q4 25 | $218.1M | $27.7M | ||
| Q3 25 | $158.0M | $12.4M | ||
| Q2 25 | $141.5M | $11.6M | ||
| Q1 25 | $98.2M | $-18.4M | ||
| Q4 24 | $207.1M | $23.7M | ||
| Q3 24 | $105.1M | $11.7M | ||
| Q2 24 | $113.5M | $9.0M |
自由现金流ASBOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | $16.8M | ||
| Q3 25 | — | $2.5M | ||
| Q2 25 | — | $4.5M | ||
| Q1 25 | — | $-25.1M | ||
| Q4 24 | — | $15.2M | ||
| Q3 24 | — | $6.3M | ||
| Q2 24 | — | $-360.0K |
自由现金流率ASBOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | 7.6% | ||
| Q3 25 | — | 1.2% | ||
| Q2 25 | — | 2.2% | ||
| Q1 25 | — | -13.0% | ||
| Q4 24 | — | 7.0% | ||
| Q3 24 | — | 3.2% | ||
| Q2 24 | — | -0.2% |
资本支出强度ASBOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | 4.9% | ||
| Q3 25 | — | 4.8% | ||
| Q2 25 | — | 3.5% | ||
| Q1 25 | — | 3.5% | ||
| Q4 24 | — | 4.0% | ||
| Q3 24 | — | 2.7% | ||
| Q2 24 | — | 4.7% |
现金转化率ASBOFIX
| Q1 26 | — | — | ||
| Q4 25 | 1.59× | — | ||
| Q3 25 | 1.27× | — | ||
| Q2 25 | 1.27× | — | ||
| Q1 25 | 0.97× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.19× | — | ||
| Q2 24 | 0.98× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASB
| Net Interest Income | $307.2M | 80% |
| Noninterest Income | $75.9M | 20% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
